COMMUNIQUÉS West-GlobeNewswire

Jasper Therapeutics to Present at Upcoming March Investor Conferences
25/02/2025
REDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]
Ardelyx to Participate in Upcoming Investor Conferences
25/02/2025
WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet [...]
ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones
25/02/2025
Anticipated registrational development plans for ORIC-944 and ORIC-114 prioritized to focus on indications with strongest clinical validation and highest unmet need ORIC-944 initiation of first Phase 3 trial in mCRPC [...]
Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia
25/02/2025
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T ™ ) products [...]
Universe Pharmaceuticals INC Receives Staff Determination Notice from Nasdaq Related to Delayed Annual Report
25/02/2025
Ji’an, Jiangxi, China, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that on February 19, 2025, the [...]
ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2024
25/02/2025
PORTLAND, Maine, Feb. 25, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and [...]
Vagus Nerve Society to host a webinar, “VNS as a Tool to Improve Focus, Energy, and Readiness in Today’s Warfighter”
25/02/2025
JACKSONVILLE, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- The Vagus Nerve Society, the preeminent association dedicated to ongoing education and training in the power of the vagus nerve, is pleased to announce its upcoming [...]
Ceribell Reports Fourth Quarter and Full Year 2024 Financial Results
25/02/2025
SUNNYVALE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]
Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston
25/02/2025
WEST CHESTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring [...]
Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress
25/02/2025
Achieved Q4 2024 and full year 2024 OJEMDA™ (tovorafenib) net product revenues of $29.0 million and $57.2 million, respectively Ended 2024 with $531.7 million in cash, cash equivalents and short-term investments Company [...]
Merit Medical Reports Fourth Quarter and Full Year 2024 Results and Issues Fiscal Year 2025 Guidance
25/02/2025
Fourth Quarter Highlights† Reported revenue of $355.2 million, up 9.4% Constant currency revenue* and constant currency revenue, organic* up 10.1% and up 6.1%, respectively GAAP operating margin of 10.3%, compared to 10 [...]
RxSight, Inc. Reports Fourth Quarter and Full-Year 2024 Financial Results, Reaffirms 2025 Guidance
25/02/2025
ALISO VIEJO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced [...]
Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025
25/02/2025
CARLSBAD, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31, 2024, before the market [...]
Bolt Biotherapeutics to Participate in Upcoming March Conferences
25/02/2025
REDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that [...]
OraSure Reports Fourth Quarter 2024 Financial Results
25/02/2025
BETHLEHEM, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for [...]
PROCEPT BioRobotics® Reports Fourth Quarter and Full Year 2024 Results
25/02/2025
SAN JOSE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in [...]
Supernus Announces Fourth Quarter and Full Year 2024 Financial Results
25/02/2025
Fourth quarter 2024 net sales of Qelbree ® increased 60% to $74.4 million, compared to the same period in 2023. Full year 2024 net sales of Qelbree increased 72% to $241.3 million, compared to full year 2023. Fourth [...]
Xenon to Present at the 45th Annual TD Cowen Healthcare Conference
25/02/2025
VANCOUVER, British Columbia and BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering [...]
Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
25/02/2025
-- Completed Successful VAX-31 Phase 2 Adult Program; Company Remains on Track to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability and Immunogenicity [...]

Pages